Last reviewed · How we verify
Donepezil drug treatment
Donepezil inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function in Alzheimer's disease.
Donepezil inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function in Alzheimer's disease. Used for Mild to moderate Alzheimer's disease, Mild cognitive impairment.
At a glance
| Generic name | Donepezil drug treatment |
|---|---|
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Acetylcholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Donepezil is a reversible inhibitor of the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. By inhibiting this enzyme, donepezil increases acetylcholine concentration in the synaptic cleft, enhancing cholinergic neurotransmission. This mechanism helps improve memory, attention, and cognitive function in patients with Alzheimer's disease, particularly in early to moderate stages.
Approved indications
- Mild to moderate Alzheimer's disease
- Mild cognitive impairment
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Muscle cramps
- Fatigue
- Insomnia
- Syncope
Key clinical trials
- Donepezil Versus Non-drug Treatment in Alzheimer's Disease. (PHASE3)
- Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease (NA)
- Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease (EARLY_PHASE1)
- Progress of Mild Alzheimer's Disease in Participants on Acupuncture Versus Sham Acupuncture (NA)
- Donepezil and Cognitive Training for Alcohol Use Disorder (AUD) (PHASE2)
- Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research
- Quality Improvement and Practice Based Research in Neurology Using the EMR (PHASE4)
- Study Safety and Efficacy of Deep Brain Stimulation (DBS) and Cervical Deep Lymphoid-venous Anastomosis (LVA) in Alzheimer's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Donepezil drug treatment CI brief — competitive landscape report
- Donepezil drug treatment updates RSS · CI watch RSS
- Shanghai Jiao Tong University School of Medicine portfolio CI